Skip to content
value.today

DexCom, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, 17.0% a year (statements).

%

US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt or cash not on file: 0 to start with.

What today's price assumes

A market value of $29.9 B means free cash flow growing 17.6% a year for 10 years, then 2.5% for ever, at a 10.15% discount rate.

Revenue grew 17.0% a year over the last three years.

Cash-flow value of the shares
$28.6 B
-4% against the market value
Value of the whole business
$28.6 B
before net debt
Value from after year 10
63%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →12.01%14.51%17.01%19.51%22.01%
8.15%-6%+14%+38%+66%+101%
9.15%-22%-6%+13%+36%+64%
10.15%-34%-20%-4%+15%+37%
11.15%-43%-31%-18%-2%+17%
12.15%-50%-40%-28%-15%+1%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

P/EP/E of Diagnostics and Research: $25.2 B to $58.0 B, median $30.0 BPrice to salesPrice to sales of Diagnostics and Research: $10.7 B to $37.3 B, median $22.6 BPrice to bookPrice to book of Diagnostics and Research: $7.5 B to $38.5 B, median $17.6 BCash-flow value$0 M$15.7 B$31.3 B$47.0 B$62.7 BMarket value $29.9 B

Your own DCF model

A full discounted-cash-flow model of DexCom, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Diagnostics and Research

Multiples of its companies with a market value at most 60 days old, times DexCom, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)DexCom, Inc.Applied toValue (25th to 75th)Companies
P/E30.1× / 35.9× / 69.4×30.2×net income $836 M$25.2 B to $58.0 B21
Price to sales2.3× / 4.8× / 8.0×5.9×revenue $4.7 B$10.7 B to $37.3 B36
Price to book2.7× / 6.4× / 14.0×10.9×book equity $2.7 B$7.5 B to $38.5 B34

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

DexCom, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

29.9×

Now below its median of 46.8×, in the bottom quarter of its range; range 26.6× to 351.2× over 29 months.

0×88×176×263×351×202120222023202420252026P/E 30×Median 47×

Price to sales

6.0×

Now below its median of 7.0×; range 4.8× to 24.1× over 30 months.

0×6×12×18×24×2020202120222023202420252026Price to sales 6×Median 7×

Price to book

10.9×

Now below its median of 13.4×, in the bottom quarter of its range; range 8.1× to 40.2× over 30 months.

0×10×20×30×40×2020202120222023202420252026Price to book 11×Median 13×

as of Oct 22, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 22, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$4.7 B$836 M$1.4 B$364 M$1.1 B—SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$4.0 B$576 M$990 M$359 M$631 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$3.6 B$542 M$749 M$237 M$512 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$2.9 B$341 M$670 M$365 M$305 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$2.4 B$217 M$443 M$389 M$53 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$1.9 B$550 M$476 M$199 M$277 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $29.9 B on Oct 22, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.